is predicted to affect the exposure to atorvastatin.
▶ Pazopanib is predicted to affect the exposure to statins
(pravastatin, rosuvastatin, simvastatin).oTheoretical
▶ Rosuvastatin is predicted to increase the anticoagulant effect
of phenindione. Monitor INR and adjust dose.rTheoretical
▶ Pibrentasvir (with glecaprevir) markedly increases the
exposure to atorvastatin. Avoid.rStudy
▶ Pibrentasvir (with glecaprevir) is predicted to increase the
exposure to fluvastatin.oTheoretical
▶ Pibrentasvir (with glecaprevir) increases the exposure to
pravastatin. Use with caution and adjust pravastatin dose,
▶ Pibrentasvir (with glecaprevir) increases the exposure to
rosuvastatin. Use with caution and adjust rosuvastatin dose,
▶ Pibrentasvir (with glecaprevir) increases the exposure to
▶ Ranolazine is predicted to increase the exposure to
▶ Ranolazine slightly increases the exposure to simvastatin.
Adjust simvastatin dose, p. 205.oStudy
▶ Regorafenib is predicted to increase the exposure to statins
(atorvastatin, fluvastatin, rosuvastatin).oStudy
▶ Ribociclib (high-dose) is predicted to increase the exposure to
simvastatin. Avoid.oTheoretical
▶ Ribociclib is predicted to increase the exposure to statins
(pravastatin, rosuvastatin).oTheoretical
▶ Rifampicin markedly decreases the exposure to atorvastatin.
Atorvastatin should be taken at the same time as rifampicin,
▶ Rifampicin moderately decreases the exposure to fluvastatin.
Monitor and adjust dose.oStudy
▶ Rifampicin very markedly decreases the exposure to
▶ Rolapitant is predicted to increase the exposure to
rosuvastatin. Monitor and adjust dose.rStudy
is predicted to increase the exposure to statins.
▶ St John’s Wort slightly decreases the exposure to atorvastatin.
▶ St John’s Wort moderately decreases the exposure to
▶ Fluvastatin slightly increases the exposure to sulfonylureas
▶ Tedizolid is predicted to increase the exposure to statins
(atorvastatin, fluvastatin, rosuvastatin). Avoid.oStudy
▶ Teriflunomide moderately increases the exposure to
rosuvastatin. Adjust rosuvastatin dose, p. 204.oStudy
▶ Teriflunomide is predicted to increase the exposure to statins
(atorvastatin, fluvastatin, pravastatin, simvastatin)
.o ▶ Ticagrelor slightly increases the exposure to simvastatin.
Adjust simvastatin dose, p. 205.oStudy
▶ Tivozanib is predicted to decrease the exposure to
▶ Velpatasvir is predicted to increase the exposure to
▶ Velpatasvir increases the exposure to rosuvastatin. Adjust
rosuvastatin dose and monitor side effects, p. 204.rStudy
▶ Velpatasvir is predicted to increase the exposure to
. Monitor side effects and adjust dose.r
▶ Venetoclax is predicted to increase the exposure to
▶ Venetoclax is predicted to increase the exposure to statins
(fluvastatin, pravastatin, rosuvastatin, simvastatin)
.o ▶ Voxilaprevir is predicted to increase the exposure to
atorvastatin. Avoid.oTheoretical
▶ Voxilaprevir (with sofosbuvir and velpatasvir) moderately
increases the exposure to pravastatin. Monitor and adjust
pravastatin dose, p. 203.oStudy
▶ Voxilaprevir (with sofosbuvir and velpatasvir) markedly
increases the exposure to rosuvastatin. Avoid.rStudy
▶ Voxilaprevir (with sofosbuvir and velpatasvir) is predicted to
increase the exposure to statins (fluvastatin, simvastatin).
Stavudine → see TABLE 12 p. 1378 (peripheral neuropathy)
▶ Didanosine increases the risk of toxicity when given with
stavudine. Avoid.rStudy → Also see TABLE 12 p. 1378
▶ Hydroxycarbamide increases the risk of toxicity when given
▶ Isoniazid is predicted to increase the risk of peripheral
neuropathy when given with stavudine.rTheoretical →
▶ Ribavirin increases the risk of toxicity when given with
▶ Zidovudine is predicted to decrease the efficacy of stavudine.
Stiripentol → see antiepileptics
Streptokinase → see TABLE 3 p. 1375 (anticoagulant effects)
Streptomycin → see aminoglycosides
Streptozocin → see TABLE 1 p. 1375 (hepatotoxicity), TABLE 2 p. 1375
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
streptozocin. Public Health England advises avoid (refer to
▶ Sucralfate is predicted to decrease the exposure to bictegravir.
▶ Sucralfate potentially decreases the effects of coumarins
. Separate administration by 2 hours.o ▶ Sucralfate decreases the absorption of digoxin. Separate
administration by 2 hours.rAnecdotal
tubes when given with enteral feeds. Separate administration
▶ Potassium citrate increases the risk of side-effects when given
with sucralfate. Avoid.oTheoretical
▶ Sucralfate decreases the exposure to quinolones. Separate
administration by 2 hours.oStudy
▶ Sodium citrate is predicted to increase the risk of side-effects
when given with sucralfate. Avoid.oTheoretical
▶ Sucralfate decreases the absorption of sulpiride. Separate
administration by 2 hours.oStudy
▶ Sucralfate potentially decreases the absorption of
. Separate administration by at least 2 hours.
▶ Sucralfate decreases the absorption of thyroid hormones
. Separate administration by at least 4 hours.
▶ Sucralfate is predicted to decrease the absorption of tricyclic
▶ Sugammadex is predicted to decrease the exposure to oral
combined hormonal contraceptives. Refer to patient
information leaflet for missed pill advice.rTheoretical
▶ Sugammadex is predicted to decrease the exposure to
desogestrel. Refer to patient information leaflet for missed pill
▶ Sugammadex is predicted to decrease the efficacy of
. Use additional contraceptive precautions.r
▶ Sugammadex is predicted to decrease the exposure to
. Use additional contraceptive precautions.
▶ Sugammadex is predicted to decrease the exposure to
medroxyprogesterone. Use additional contraceptive
▶ Sugammadex is predicted to decrease the exposure to
. Use additional contraceptive precautions.
Sulfadiazine → see sulfonamides
Sulfadoxine → see sulfonamides
Sulfamethoxazole → see sulfonamides
Sulfasalazine → see TABLE 1 p. 1375 (hepatotoxicity), TABLE 15 p. 1378
▶ Antifungals, azoles (isavuconazole) are predicted to increase the
exposure to sulfasalazine.oTheoretical
decreases the concentration of digoxin.o ▶ Sulfasalazine
is predicted to decrease the absorption of folates.
▶ Leflunomide is predicted to increase the exposure to
sulfasalazine.oStudy → Also see TABLE 1 p. 1375 → Also see
▶ Regorafenib is predicted to increase the exposure to
sulfasalazine.oStudy → Also see TABLE 15 p. 1378
▶ Rolapitant increases the exposure to sulfasalazine.rStudy
▶ Tedizolid is predicted to increase the exposure to sulfasalazine.
▶ Teriflunomide is predicted to increase the exposure to
1536 Statins — Sulfasalazine BNF 78
▶ Velpatasvir is predicted to increase the exposure to
▶ Venetoclax is predicted to increase the exposure to
▶ Voxilaprevir is predicted to increase the concentration of
sulfasalazine. Avoid.rTheoretical
Sulfonamides → see TABLE 15 p. 1378 (myelosuppression)
sulfadiazine . sulfadoxine . sulfamethoxazole. ▶ Sulfonamides potentially increase the risk of
methaemoglobinaemia when given with topical anaesthetics,
local (prilocaine). Use with caution or avoid.rAnecdotal
▶ Sulfadiazine is predicted to increase the concentration of
antiepileptics (fosphenytoin). Monitor and adjust dose.
▶ Sulfadiazine increases the concentration of antiepileptics
(phenytoin). Monitor and adjust dose.oStudy
▶ Antimalarials (pyrimethamine) increase the risk of side-effects
when given with sulfonamides.rStudy → Also see TABLE 15
▶ Sulfadiazine is predicted to increase the anticoagulant effect
▶ Sulfamethoxazole increases the anticoagulant effect of
▶ Sulfonamides are predicted to increase the risk of
methaemoglobinaemia when given with dapsone.r
▶ Sulfonamides are predicted to increase the exposure to
methotrexate. Use with caution or avoid.rTheoretical →
▶ Potassium aminobenzoate is predicted to affect the efficacy of
sulfonamides. Avoid.rTheoretical
▶ Sulfonamides are predicted to increase the exposure to
▶ Sulfonamides are predicted to increase the effects of
Sulfonylureas → see TABLE 14 p. 1378 (antidiabetic drugs)
sulfonylureas. Use with caution and adjust dose.
▶ Antifungals, azoles (fluconazole, miconazole) are predicted to
increase the exposure to sulfonylureas. Use with caution and
▶ Antifungals, azoles (voriconazole) are predicted to increase the
concentration of sulfonylureas. Use with caution and adjust
▶ Bosentan increases the risk of hepatotoxicity when given with
▶ Cephalosporins (ceftobiprole) are predicted to increase the
concentration of glibenclamide.oTheoretical
▶ Ceritinib is predicted to increase the exposure to glimepiride.
▶ Chloramphenicol is predicted to increase the exposure to
▶ Fibrates are predicted to increase the risk of hypoglycaemia
when given with sulfonylureas.oTheoretical
▶ Leflunomide is predicted to increase the exposure to
▶ Letermovir is predicted to increase the concentration of
▶ Macrolides (clarithromycin) are predicted to slightly increase
the exposure to sulfonylureas.oTheoretical
▶ Rifampicin is predicted to decrease the exposure to
▶ Statins (fluvastatin) slightly increase the exposure to
▶ Sulfonamides are predicted to increase the exposure to
▶ Teriflunomide is predicted to increase the exposure to
▶ Venetoclax is predicted to increase the exposure to
▶ Antacids decrease the absorption of sulpiride. Separate
administration by 2 hours.oStudy
▶ Sulpiride is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Sulpiride is predicted to decrease the effects of levodopa.
Avoid.rTheoretical → Also see TABLE 8 p. 1376
▶ Sulpiride potentially increases the risk of neurotoxicity when
given with lithium.rAnecdotal → Also see TABLE 9 p. 1377
▶ Sucralfate decreases the absorption of sulpiride. Separate
administration by 2 hours.oStudy
Sumatriptan → see TABLE 13 p. 1378 (serotonin syndrome)
▶ Sumatriptan increases the risk of vasoconstriction when given
with ergotamine. Ergotamine should be taken at least 24 hours
before or 6 hours after sumatriptan.rStudy
▶ Moclobemide moderately increases the exposure to
sumatriptan. Avoid.oStudy → Also see TABLE 13 p. 1378
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the exposure to sumatriptan. Avoid and
for 14 days after stopping the MAOI.rTheoretical → Also
Sunitinib → see TABLE 15 p. 1378 (myelosuppression), TABLE 9 p. 1377
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to sunitinib.oTheoretical → Also see TABLE 9
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
are predicted to increase the exposure to
Theoretical → Also see TABLE 9 p. 1377
sunitinib.o ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to slightly increase the exposure to sunitinib. Avoid
No comments:
Post a Comment
اكتب تعليق حول الموضوع